Celldex Therapeutics, Inc. — Q1 2015 Form 10-Q
Reporting period: Three months ended March 31, 2015; compared with the three months ended March 31, 2014. Celldex is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and other difficult-to-treat diseases. Financial statements are unaudited.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / comparator |
|---|---|---|
| Revenue | $0.5 million | $0.4 million; up 17% |
| Research and development expense | $25.1 million | $27.1 million; down 7% |
| General and administrative expense | $6.1 million | $4.6 million; up 33% |
| Operating loss | $31.0 million | $31.5 million |
| Net loss | $30.2 million | $29.9 million |
| Basic and diluted loss per share | $0.33 | $0.33 |
| Net cash used in operations | $32.6 million | $31.9 million |
- At March 31, cash and cash equivalents were $122.2 million and marketable securities were $237.6 million, totaling approximately $359.8 million. Current assets were $364.1 million and current liabilities were $21.1 million.
- Stockholders’ equity was $375.6 million; total liabilities were $32.1 million. The filing does not identify conventional funded debt as a material balance-sheet item.
- Cash flow from financing was $191.8 million, primarily from a March public offering of 8.34 million shares that generated $188.8 million net proceeds. Shares outstanding increased from 89.6 million at year-end to 98.5 million at March 31.
- Investing activities used $65.0 million, including net purchases of marketable securities and $1.6 million of property and equipment. The company reported no material exposure to likely interest-rate changes.
Changes versus the prior period
- Revenue rose $0.1 million. Product development and licensing revenue increased to $0.3 million, principally from recognition of the BMS collaboration payment; contracts and grants revenue declined to $0.1 million, primarily reflecting the Rockefeller agreement.
- R&D expense fell $1.9 million. Lower product-development costs, including reduced ACT IV costs, and the absence of a $2.5 million Seattle Genetics milestone recorded in Q1 2014 more than offset higher personnel and supply costs.
- G&A expense rose $1.5 million, reflecting higher stock-based compensation, increased headcount, and commercial-planning costs for Rintega and glembatumumab vedotin.
- Investment and other income declined $0.8 million, mainly because Q1 2014 included a $1.0 million TopoTarget milestone payment. Net loss increased slightly despite lower operating expense.
Outlook, programs, and risks
- Management said the March 31 liquidity balance was expected to fund planned operations through 2017, while the financial-statement note described resources as sufficient for at least the next 12 months. The company cautioned that clinical results, particularly for Rintega, and resulting commercial-manufacturing and operating plans could affect cash needs. It expected operating cash use, personnel costs, and G&A to increase over the next 12 months.
- Rintega: FDA granted Breakthrough Therapy Designation in February 2015. Enrollment in the pivotal ACT IV Phase 3 trial was complete; the first interim analysis was expected in mid-2015, a second in late 2015 or early 2016, and final data by year-end 2016, subject to event rates. Management planned to present final ReACT Phase 2 data in May 2015.
- Glembatumumab vedotin: METRIC Phase 2b enrollment was projected to complete in 2016 after protocol changes intended to support full U.S. and European marketing approval. A melanoma Phase 2 study was underway; a squamous-cell lung cancer study was expected to begin in the second half of 2015.
- Varlilumab: A BMS Opdivo combination Phase 1/2 trial began in January 2015. A Roche combination study in renal cell carcinoma was expected to begin in the second half of 2015. Other combination programs were ongoing or under development.
- Other developments: A varlilumab/Yervoy study began in April 2015, after quarter-end. CDX-014 manufacturing and IND-enabling work was expected to support potential Phase 1 initiation in 2016.
- Key risks include clinical-trial safety and efficacy outcomes, regulatory approval and timing, manufacturing and supplier availability, competition, intellectual-property challenges, and the need for additional financing. Further equity financing could dilute shareholders; debt could add payment and covenant obligations; collaboration or licensing terms could reduce product economics. The company said there were no material changes to previously disclosed risk factors.
- Celldex stated that existing cash and securities were expected to cover near-term plans, but it may seek additional capital or collaborations for longer-term needs; availability and terms are not assured. No specific financial guidance was provided.
Important facts for investors to verify
- ACT IV interim and final data timing, event rates, and results, and the clinical significance of ReACT findings.
- METRIC enrollment progress, trial execution, and whether its design and eventual data can support approval in the United States and Europe.
- Actual quarterly cash burn and whether the stated runway through 2017 remains consistent with development and potential commercial-preparation spending.
- Potential dilution and capital needs following the 2015 public offering, including any additional financing or partnership terms.
- How much reported revenue depends on recognition of previously received collaboration payments and service agreements rather than product sales.